Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$84.28 USD

84.28
4,852,622

+1.23 (1.48%)

Updated Sep 18, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why

The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.

Gilead Stock Rises as HIV Prevention Injection Meets Study Goals

GILD reports the success of its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, in a second late-stage study for the prevention of HIV.

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

Gilead Sciences (GILD) reachead $81.01 at the closing of the latest trading day, reflecting a -0.53% change compared to its last close.

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Smart Beta ETF report for PBE

Neena Mishra headshot

Why Biotech ETFs Are Beating the Market

: Biotech stocks are poised to benefit from lower rates

Should Pacer US Cash Cows 100 ETF (COWZ) Be on Your Investing Radar?

Style Box ETF report for COWZ

Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?

While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.

Is Pacer US Cash Cows 100 ETF (COWZ) a Strong ETF Right Now?

Smart Beta ETF report for COWZ

Sheraz Mian headshot

Top Stock Reports for Texas Instruments, Union Pacific & Vertex Pharmaceuticals

Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), Union Pacific Corporation (UNP) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks Tile Shop Holdings, Inc. (TTSH) and Gencor Industries, Inc. (GENC).

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Ekta Bagri headshot

Biotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News

Bigwigs Regeneron (REGN) and Gilead Sciences (GILD) are in the spotlight following regulatory updates and drug approval, respectively.

Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi

Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.

Ekta Bagri headshot

Bristol Myers (BMY) Gains 16% in a Month: Should You Buy or Wait?

Bristol Myers' (BMY) impressive second-quarter results propelled the stock in the past month. However, we advise investors not to be over-optimistic at this point and look before they leap.

Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised

Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.

Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates

Gilead (GILD) delivered earnings and revenue surprises of 24.84% and 4.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Continuing Claims Hit Highest Since Nov 2021

Continuing Claims Hit Highest Since Nov 2021

Jobless Claims Decline, Pre-Markets in the Green

It???s a big day for Wall Street as the much-awaited Jobless Claims numbers are out, which could be a major factor in market moves for the rest of the week.

2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 17.14% and 21.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 52.63% and 156.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Kanishka Das headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.

Will 2seventy bio, Inc. (TSVT) Report Negative Q2 Earnings? What You Should Know

2seventy bio, Inc. (TSVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.